TY - JOUR
T1 - Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma
AU - Sedda, A. F.
AU - Rossi, G.
AU - Cipriani, C.
AU - Carrozzo, A. M.
AU - Donati, P.
PY - 2008/11
Y1 - 2008/11
N2 - Background. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans. Various therapies are currently being used to treat these tumours including surgery, topical treatments and radiotherapy. We describe a new treatment for BCC and SCC. This consists of superficial radiotherapy, using synthetic resin containing a radioactive β-emitting isotope. The resin is applied to the lesion to perform a selective β-irradiation brachytherapy treatment. Methods. In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment. Results. In all treated cases, an apparent clinical remission occurred in approximately 3 months, and complete healing was obtained in 100% of the treated patients; in 82% of the cases, this occurred after a single application. No disfiguring scars or any side-effects were seen. After a follow-up of 20-72 months (mean 51 months), no clinical relapses were observed in the treated patients. Histological examination confirmed complete tumour regression. Conclusion. The results indicated that brachytherapy is an effective treatment for BCC and SCC.
AB - Background. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are among the most common cancers in humans. Various therapies are currently being used to treat these tumours including surgery, topical treatments and radiotherapy. We describe a new treatment for BCC and SCC. This consists of superficial radiotherapy, using synthetic resin containing a radioactive β-emitting isotope. The resin is applied to the lesion to perform a selective β-irradiation brachytherapy treatment. Methods. In total, 53 patients with histologically confirmed diagnosis of BCC and of SCC were enrolled for the treatment. Results. In all treated cases, an apparent clinical remission occurred in approximately 3 months, and complete healing was obtained in 100% of the treated patients; in 82% of the cases, this occurred after a single application. No disfiguring scars or any side-effects were seen. After a follow-up of 20-72 months (mean 51 months), no clinical relapses were observed in the treated patients. Histological examination confirmed complete tumour regression. Conclusion. The results indicated that brachytherapy is an effective treatment for BCC and SCC.
UR - http://www.scopus.com/inward/record.url?scp=53349089944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53349089944&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2230.2008.02852.x
DO - 10.1111/j.1365-2230.2008.02852.x
M3 - Article
C2 - 18681873
AN - SCOPUS:53349089944
VL - 33
SP - 745
EP - 749
JO - Clinical and Experimental Dermatology
JF - Clinical and Experimental Dermatology
SN - 0307-6938
IS - 6
ER -